Acta Pharmaceutica Sinica B
|
2026, 16(1): 651-655
• Highlights •
Clinical insight-driven novel drug development: Multidisciplinary integration and transformative opportunities
Full
Baohu Li1,2, Hui Xu1, Xiaoyu Shi1, Chunhua Ma3, Jinfei Yang2, Peng Zhan1
Affiliations
1 Department of Medicinal Chemistry, Shandong Key Laboratory of Druggability Optimization and Evaluation for Lead Compounds, School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China;
2 School of Health and Life Sciences, University of Health and Rehabilitation Sciences, Qingdao 266001, China;
3 State Key Laboratory of Antiviral Drugs, School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang 453007, China
doi: 10.1016/j.apsb.2025.10.047
Outline
Parkinson's disease
/
Prostate cancer
/
Non-alcoholic steatohepatitis
/
FAM171A2
/
ADAR1
/
SMPD3
/
Clinical-cohort-driven
/
Multi-omics integration
Baohu Li, Hui Xu, Xiaoyu Shi, Chunhua Ma, Jinfei Yang, Peng Zhan.
Clinical insight-driven novel drug development: Multidisciplinary integration and transformative opportunities[J].
Acta Pharmaceutica Sinica B,
2026
, 16
(1)
: 651
-655
.
DOI: 10.1016/j.apsb.2025.10.047
Year 2026 volume 16 Issue 1
PDF
6
4
Cite this Article
BibTeX
Article Info
doi: 10.1016/j.apsb.2025.10.047
- Receive Date:2025-05-29
- Online Date:2026-09-17